Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.
Journal: Future oncology (London, England)
Published: July 16, 2026
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung Cancer.
Journal: JCO precision oncology
Published: June 18, 2026
QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: April 15, 2026
QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 17, 2025
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Journal: JTO clinical and research reports
Published: October 21, 2025
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2025
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
Journal: Molecular cancer therapeutics
Published: September 05, 2025
Last Updated: 09/26/2026